Epiretinal Membrane Surgery after Retinal Detachment Repair: Visual Acuity Outcomes and OCT Analysis

Written by: Daniel Su, MD October 2021 Soares RR, Mahmoudzadeh R, Salabati M, Massenzio E, Israilevich R, Patel SN, Hinkle J, Kuriyan AE, Hsu J, Garg SJ, Khan MA. Epiretinal Membrane Surgery after Retinal Detachment Repair: Visual Acuity Outcomes and OCT Analysis. Ophthalmol Retina. 2021 Mar 29:S2468-6530(21)00103-2. Epiretinal membrane (ERM) formation commonly occurs after primary […]

Microcystic Macular Edema and Cystoid Macular Edema Before and After Epiretinal Membrane Surgery

Written by: Edward H. Wood, MD September 2021 Lee Dong Hyun, Sung Eun Park, and Christopher Seungkyu Lee. 2020. “Microcystic Macular Edema and Cystoid Macular Edema Before and After Epiretinal Membrane Surgery.” Retina Publish Ahead of Print (December). https://doi.org/10.1097/IAE.0000000000003087. This study is clinically useful by expanding our understanding of imaging biomarkers of idiopathic epiretinal membranes (ERM) […]

Machine Learning Can Predict Anti–VEGF Treatment Demand in a Treat-and-Extend Regimen for Patients with Neovascular AMD, DME, and RVO Associated Macular Edema

Written by: Mohsin H. Ali, MD September 2021 Gallardo, Mathias, et al. “Machine Learning Can Predict Anti–VEGF Treatment Demand in a Treat-and-Extend Regimen for Patients with Neovascular AMD, DME, and RVO Associated Macular Edema.” Ophthalmology Retina, vol. 5, no. 7, 2021, pp. 604–624., doi:10.1016/j.oret.2021.05.002.  Machine learning artificial intelligence models have the potential to improve our […]

Two-year results of the phase 3 randomized controlled study of abicipar in neovascular age-related macular degeneration

Written by: Akshay S. Thomas, MD August 2021 Khurana RN, Kunimoto D, Yoon YH, et al. Two-year results of the phase 3 randomized controlled study of abicipar in neovascular age-related macular degeneration. Ophthalmology. 2021;128(7):1027-1038.   Treatment options for wet AMD in 2019 included off-label use of bevacizumab or use of an FDA-approved agent, ranibizumab or […]

Long-term anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: the LATAR study. Report 1: ten-year, real-world outcomes.

Written by: Vlad Matei, MD August 2021 Spooner K, Fraser-Bell S, Hong T, et al. Long-term anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: the LATAR study. Report 1: ten-year, real-world outcomes. Ophthalmology Retina 2021;5(6):511-518. Neovascular age-related macular degeneration (nAMD) is one of the most common and debilitating diseases encountered by retinal specialists. […]

Pneumatic Vitreolysis with C3F8 for Vitreomacular Traction with and without Macular Hole: DRCR Retina Network Protocols AG and AH

Written by: Joshua D. Levinson, MD August 2021 Chan CK, Mein CE, Glassman AR, et al. Pneumatic Vitreolysis with C3F8 for Vitreomacular Traction with and without Macular Hole: DRCR Retina Network Protocols AG and AH. Ophthalmol. 2021 Treatment options for symptomatic vitreomacular traction (VMT) and macular hole (MH) include observation, pars plana vitrectomy and vitreolysis. […]

Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice

Written by: Christopher Aderman, MD July 2021 Maloney MH, Payne SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice. Ophthalmology. 2021 Mar;128(3):417-424. doi: 10.1016/j.ophtha.2020.07.062. Epub 2020 Aug 8. PMID: 32781110. An unfortunate problem we encounter not infrequently in clinic is […]

Clinical Outcomes and Treatment Course of Eyes with Neovascular Age-Related Macular Degeneration Following the Development of Endophthalmitis

Written by: Judy Chen, MD July 2021 Koulisis N, Moysidis S, Govindaraju V, et al. Clinical Outcomes and Treatment Course of Eyes with Neovascular Age-Related Macular Degeneration Following the Development of Endophthalmitis. Retina 2021; 41(6):1242-1250. Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) medication are the current gold standard of care for patients with neovascular […]